SteroTherapeutics

SteroTherapeutics is seeking a novel drug therapy for non-alcoholic steatohepatitis (NASH), which has been predicted to be the next major health epidemic. This situation is critical as there are no approved treatments for NASH, and it is a leading cause of liver-related morbidity and mortality. Analysts predict that the NASH treatment market could reach between $35-$40 billion by 2025.